tbuckley/cabot-search huggingface dataset:
Antibody- and Cell-Mediated Immune Thrombocytopenia Are Differentially Sensitive to Intravenous Gammaglobulin Therapy
Authors: Leola Chow, Michael Kim, Edwin R. Speck, Rukhsana Aslam, Michelle Lee Webster, Pingguo Chen, Heyu Ni, John Freedman, John W. Semple
Journal: Blood (2008)
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial
Authors: Donald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, Ellen Dahler, Robin Besuyen, Will Sawyer, Stéphane Bolduc, Søren Rittig
Journal: European Urology (2016)
POSTOPERATIVE RADIOTHERAPY IN RESECTED STAGE III-N2 NON-SMALL CELL LUNG CANCER (NSCLC): CAN 3D-CONFORMAL RADIOTHERAPY IMPROVE THE 5-YEAR OVERALL SURVIVAL (OS) IN PATIENTS WITH PERSISTENT N2 DISEASE AFTER INDUCTION CHEMOTHERAPY?
Authors: Céline Billiet, Z Gouw, H Decaluwe, Stéphanie Peeters, Johan Vansteenkiste, Christophe Dooms, Paul De Leyn, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2014)
Detrimental Side Effects of Repeated Ketamine Infusions in the Brain
Authors: Kenji Hashimoto
Journal: American Journal of Psychiatry (2016)

This raises the enduring question of the relationship between physical pain, mental pain, and suicidality.As reviewed by Elman et al. (2), several lines of evidence suggest that the colloquial terms "broken heart" and "heartache" may reflect a sad existential truth: mental pain hurts so much that it may lead to suicide.Since Shakespeare's "To be, or not to be" monologue, in which Prince Hamlet contemplates suicide in order to "end the Heart-ache" (3), mental pain has been associated with suicidality in poetry and prose.Many, and perhaps most, suicidal individuals who come to the attention of mental health professionals seek death not because they want to stop living but because they want to stop suffering.In a recent systematic review, Verrocchio et al. concluded that "mental pain is a core clinical factor for understanding suicide" (4).Specifically, they found mental pain to be a stronger factor of vulnerability for suicidal ideation than depression.Mood symptoms may be experienced and described as physical pain in some cultures, and mood and somatic symptoms are often positively correlated (5).However, we agree with Verrocchio et al. that mental pain "is no less real than other types of grief" (4).In our opinion, clinicians should be open to the possibilitynot the certainty-that judicious short-term use of ultra-lowdose buprenorphine may quickly decrease severe suicidal ideation by ameliorating the experience of mental pain.
Predicting outcomes in interstitial lung disease
Authors: T Corte, S Talbot, S Wort, S Sanderson, H Lockstone, N Kulakova, D Baban, C Newbold, A Mcmichael, L-P Ho
Journal: Thorax (2009)

Nocturnal desaturation is present in 30-40% of patients with interstitial lung disease (ILD), and may be associated with poorer quality of life.However, the prognostic impact of nocturnal desaturation is not well established in patients with ILD.Aim To assess the prognostic utility of parameters of nocturnal desaturation across ILD.Methods Patients with ILD with overnight oximetry from June 2006 to August 2008 were reviewed (n = 139, age 59¡13 years, 51 male, body mass index (BMI) 28¡7 kg/m 2 ).All patients had corresponding pulmonary function, 133 had echocardiography and 123 had brain natriuretic peptide (BNP).Patients were followed to death, last follow-up or 19 March 2009.Outcome was evaluated for mortality using Cox proportional hazards analysis.The desaturation index (DI) was defined as the number of desaturation events .4% per hour of study time.Pulmonary hypertension (PH) was defined as systolic pulmonary arterial pressure >50 mm Hg or right heart dilatation on echocardiography.Results Nocturnal desaturation was present in 50 (36%) patients, and mean minimum SpO 2 was 76.3¡9.9%.Twenty-eight (20%) had PH on echocardiography.An increased DI was associated with higher mortality independent of age, gender and BMI (hazards ratio (HR) 1.04; 95% CI 1.00 to 1.08; p = 0.007).In separate models, DI and (1) elevated BNP (HR 1.01; CI 1.00 to 1.02; p = 0.03); (2) PH on echocardiography (HR 23.27; CI 1.28 to 8.31; p = 0.01); and (3) daytime resting SpO 2 (HR 0.92; CI 0.85 to 0.99; p = 0.03) independently predicted mortality following adjustment for age, gender and BMI.Conclusion Elevated nocturnal DI predicts higher mortality across patients with ILD, independent of BNP and PH on echocardiography and resting daytime SpO 2 .DI may be an important prognostic consideration for patients with ILD, and warrants further prospective study.
Gadolinium-mesoporphyrin-enhanced magnetic resonance imaging allows precise non-invasive measurements of infarct size after thrombolytic therapy
Authors: S Pislaru, Yicheng Ni, C Pislaru, Hilde Bosmans, Y Miao, Jan Bogaert, Guy Marchal, Frans Van de Werf, W Semmler
Journal: Circulation (1997)
O100 : The hepatic microenvironment induces a CSC phenotype and determines the prognosis of HCC patients
Authors: D. Castven, M. Fischer, S. Heinrich, J.B. Andersen, M.F. Sprinzl, I. Gockel, S. Heilmann, M.A. Wörns, S.S. Thorgeirsson, P.R. Galle, H. Lang, J.U. Marquardt
Journal: Journal of Hepatology (2015)
30-year risk of myocardial infarction, stroke, or coronary death in childhood cancer survivors.
Authors: T. L. Miller, D. C. Landy, G. V. Lopez-Mitnik, S. R. Lipsitz, A. S. Hinkle, L. S. Constine, C. A. French, A. M. Rovitelli, M. J. Adams, S. E. Lipshultz
Journal: Journal of Clinical Oncology (2010)

e19541 Background: Concerns that survivors face an increased burden from atherosclerosis have led to recommendations for early testing of traditional risk factors such as cholesterol and their aggressive treatment. These recommendations, however, provide no method for aggregating test results or estimating the cumulative risk from traditional risk factors. This may now be possible using the recently developed Framingham Heart Study's calculator (FHC) that predicts 30-yr risk of CVD (myocardial infarction [MI], stroke, or coronary death) in those over 20 yrs old. Methods: Risk factors were measured in a representative sample of 73 survivors and 17 siblings over 20 yrs old in an NCI prospective cohort study in Rochester, NY, from 1999-2004. Risk factors were aggregated using the FHC, a weighted combination of age, sex, total cholesterol, HDL-cholesterol, smoking, BP, diabetes, and hypertensive treatment. FHC estimates for survivors were compared to siblings after adjusting for age and sex. Results: Survivors were a mean 28 yrs of age and 17 yrs since diagnosis (dx); 49% received anthracyclines, 57% cardiac radiation, 38% cranial radiation, and 4% total body radiation, as part of multiagent therapy. Survivors had 52% (p = 0.22) increased risk vs. siblings. Among survivors from the Long-Term Survivors Study (LTSS), median age of 56 yrs and 48 yrs since dx, 17% reported coronary artery disease and 4% reported cerebral vascular disease. Among survivors from the Childhood Cancer Survivor Study (CCSS), 30 yrs since dx, 1.5% reported MI. Conclusions: The high risk of CVD predicted by the FHC using traditional risk factors and the comparability of this estimate to rates observed in the LTSS and CCSS suggest traditional risk factors account for much of the CVD in survivors, though cancer treatments such as radiation add additional independent risk not captured by the FHC. Our findings and variations in risk estimates confirm screening recommendations and suggest the easy to use and cost-free FHC may help identify survivors in need of further assessment. Mean (range) FHC risk estimate for survivors by age group and sex 20-29-yr-old females 20-29-yr-old males 30-39-yr-old females 30-39-yr-old males 2.1% (1-9%) 3.3% (1-12%) 2.9% (1-5%) 15.6% (5-35%) No significant financial relationships to disclose.
Paired comparison of the sensitivity and specificity of multispectral digital skin lesion analysis and reflectance confocal microscopy in the detection of melanoma in vivo: A cross-sectional study
Authors: Eunice Song, Jane M. Grant-Kels, Helen Swede, Jody L. D'Antonio, Avery Lachance, Soheil S. Dadras, Arni K. Kristjansson, Katalin Ferenczi, Hanspaul S. Makkar, Marti J. Rothe
Journal: Journal of the American Academy of Dermatology (2016)
PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer
Authors: Marc Peeters, Jean-Yves Douillard, Eric Van Cutsem, Siena Salvatore, Kathy Zhang, Richard Williams, Jeffrey Wiezorek
Journal: Annals of Oncology (2012)
Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
Authors: Victor Bengt Pastor Loyola, Shinsuke Hirabayashi, Sandra Pohl, Emilia J Kozyra, Albert Catala, Barbara De Moerloose, Michael Dworzak, Henrik Hasle, Riccardo Masetti, Markus Schmugge, Owen Smith, Jan Starý, Marek Ussowicz, Marry M. van den Heuvel-Eibrink, Ester Mejstrikova, Ulrich Salzer, Michael Lübbert, Daniel Heudobler, David Betts, Jose Cervera, Gudrun Göhring, Oskar A. Haas, Olga Haus, Kyra Michalova, Francesco Pasquali, Joelle Tchinda, Nadine van Roy, Brigitte Schlegelberger, H. Berna Beverloo, Peter Noellke, Ayami Yoshimi, Franco Locatelli, Brigitte Strahm, Jaroslaw P. Maciejewski, Michael Rehli, Charlotte M Niemeyer, Marcin W Wlodarski
Journal: Blood (2015)
A Small Molecule Inhibitor of the CBFβ-SMMHC/RUNX Interaction Attenuates Inv(16) Leukemia in Vivo
Authors: John H. Bushweller, Anuradha Illendula, John Anto Pulikkan, Jolanta Grembecka, Paul Bradley, Yunpeng Zhou, Liting Xue, Yan Gao, Lucio H. Castilla
Journal: Blood (2012)
Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126
Authors: H. West, K. Chansky, W. A. Franklin, F. R. Hirsch, J. J. Crowley, D. H. Lau, D. R. Gandara
Journal: Journal of Clinical Oncology (2008)

8047 Background: BAC, a non-small cell lung cancer (NSCLC) subtype with distinctive clinical, pathologic, and radiographic characteristics, remains without an accepted standard of care for advanced, multi-focal disease. Outcomes with chemotherapy are reported to be poor, and sensitivity to EGFR inhibitor therapy high. SWOG initiated S0126 to determine the activity and tolerability of gefitinib therapy, and to determine clinical and molecular variables associated with outcomes. We previously reported clinical results with a median follow-up of 22 months (West et al, JCO, 2006) as well as molecular variables of EGFR FISH status and activating mutations in a subset of S0126 patients (Hirsch et al., Ann Oncol 2006). Methods: Here we update long-term results for 135 eligible patients (100 chemo-naive, 35 previously treated) who received gefitinib 500 mg PO daily until progression or prohibitive toxicity. Results: With a median follow-up of 58 months (minimum 38 mos.), median progression-free survival (PFS) and overall survival (OS) remain at 4/3 and 13/13 months, for treatment-naïve/previously treated cohorts, respectively. Three year survival is 27% for the chemo-naïve stratum and 20% for previously treated. Five-year survival is 12% (14% for pretreated). Patients surviving ≥ 3 years were more likely to be EGFR positive by FISH (50% FISH+ vs 26% for patients surviving < 3yrs, p=.058, N=81 cases with a FISH result). 6 patients remained on treatment without progression > four years; at present 3 patients, all treatment-naïve, remain without evidence of progression at 56–67 months from initiation of treatment; Two are EGFR FISH+, one with an exon 21 mutation. Conclusions: Long term survival of 27% at 3 years compares favorably to prior SWOG chemotherapy data in advanced BAC. A subset of these patients continue to demonstrate PFS > 4–5 years (CA32102, CA38926) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca AstraZeneca
Disparity In Clinical Outcomes Of Elderly Patients With Non-Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation According To Area Of Residence
Authors: Andrew C. Cannon, James Olen Armitage, Philip Bierman, R. Gregory Bociek, Julie M. Vose, Fausto R. Loberiza
Journal: Blood (2013)
Haploidentical, Unmanipulated, G-CSF-Primed Bone Marrow Transplantation For Patients With High-Risk Acute Myeloid Leukemia
Authors: William Arcese, Raffaella Cerretti, Stella Santarone, Alessandra Picardi, Manuela Testi, Laura Cudillo, Francesco Buccisano, Teresa Dentamaro, Fabio Di Piazza, Gottardo De Angelis, Paolo Di Bartolomeo
Journal: Blood (2013)
Re: Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies RESPONSE
Authors: W.-C. Liao, W.-S. W. Chang, F. Y.-H. Wu, M. Aghi, T.-C. Chou, X. O. Breakefield, E. A. Chiocca
Journal: JNCI Journal of the National Cancer Institute (1999)
Gene expression elucidates functional impact of polygenic risk for schizophrenia
Authors: Menachem Fromer, Panos Roussos, Solveig K Sieberts, Jessica S Johnson, David H Kavanagh, Thanneer M Perumal, Douglas M Ruderfer, Edwin C Oh, Aaron Topol, Hardik R Shah, Lambertus L Klei, Robin Kramer, Dalila Pinto, Zeynep H Gümüş, A Ercument Cicek, Kristen K Dang, Andrew Browne, Cong Lu, Lu Xie, Ben Readhead, Eli A Stahl, Jianqiu Xiao, Mahsa Parvizi, Tymor Hamamsy, John F Fullard, Ying-Chih Wang, Milind C Mahajan, Jonathan M J Derry, Joel T Dudley, Scott E Hemby, Benjamin A Logsdon, Konrad Talbot, Towfique Raj, David A Bennett, Philip L De Jager, Jun Zhu, Bin Zhang, Patrick F Sullivan, Andrew Chess, Shaun M Purcell, Leslie A Shinobu, Lara M Mangravite, Hiroyoshi Toyoshiba, Raquel E Gur, Chang-Gyu Hahn, David A Lewis, Vahram Haroutunian, Mette A Peters, Barbara K Lipska, Joseph D Buxbaum, Eric E Schadt, Keisuke Hirai, Kathryn Roeder, Kristen J Brennand, Nicholas Katsanis, Enrico Domenici, Bernie Devlin, Pamela Sklar
Journal: Nature Neuroscience (2016)
A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).
Authors: Francis Giles, H. Kantarjian, B. Wassmann, J. Cortes, S. O’Brien, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, O. Ottmann
Journal: Blood (2004)
The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling
Authors: Jin Li, Tamara Riedt, Steven Goossens, Carmen Carrillo García, Sabrina Szczepanski, Maria Brandes, Tim Pieters, Linne Dobrosch, Ines Gütgemann, Natalie Farla, Enrico Radaelli, Paco Hulpiau, Nikhil Mallela, Holger Fröhlich, Roberta La Starza, Caterina Matteucci, Tong Chen, Peter Brossart, Cristina Mecucci, Danny Huylebroeck, Jody J. Haigh, Viktor Janzen
Journal: Blood (2016)
Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years
Authors: Maria-Victoria Mateos, Joaquín Martínez-López, Miguel T Hernandez, Enrique M Ocio, Laura Rosiñol, Rafael Martinez, Ana Isabel Teruel, Norma C Gutierrez, María-Luisa Martín, Albert Oriol, Joan Bargay, Enrique Bengoechea, Yolanda Gonzalez, Jaime Perez de Oteyza, Mercedes Gironella, Cristina Encinas, Carmen Cabrera, Bruno Paiva, Maria Teresa Cedena, Noemi Puig, Joan Blade, Juan José Lahuerta, Jesus San Miguel
Journal: Blood (2015)
Treating obesity as scientific behavioural problem
Authors: Falko F Sniehotta, Susan Michie, Marie Johnston
Journal: BMJ (2005)

Jain’s (BMJ 9/12/05) review of interventions for treating obesity in individuals and populations concludes that current evidence indicated individually based treatments to be weakly effective and to lack a major impact on the obesity epidemic. Based on her review, she calls for public health interventions rather than individual interventions and suggests a redefinition of the concept of evidence informing public health interventions.
A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).
Authors: John Mascarenhas, Xiaoli Wang, Amelyn Rodriguez, Mingjiang Xu, Elaine Gorman, Wenyong Zhang, Judith D. Goldberg, Vesna Najfeld, Ronald Hoffman
Journal: Blood (2009)
International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia
Authors: Heike Pfeifer, Giovanni Cazzaniga, Orietta Spinelli, Jean-Michel Cayuela, Hélène Cavé, Peter Vandenberghe, Carmen Chillon, Tomasz Sacha, Sandrine Hayette, Silja Roettgers, Thomas Lion, Letizia Foroni, Vincent H.J. van der Velden, Jan Zuna, Monica Hermanson, Martin Christian Mueller, Thoralf Lange, Miroslaw Majewski, Israel Bendit, Fabrizio Pane, Ilaria Iacobucci, Veli Kairisto, Christa Homburg, Smadar Avigad, Eng Juh Allen Yeoh, Beat Schäfer, Adele Fielding, Loredana Elia, Katarzyna Borg, Eric Delabesse, Susanne Schnittger, Sandra Markovic, Volker Werner, Nicola Goekbuget, Dieter Hoelzer, Jacques J.M. van Dongen, Oliver G. Ottmann
Journal: Blood (2011)
Reallocation of Olfactory Cajal-Retzius Cells Shapes Neocortex Architecture
Authors: Cristina A. de Frutos, Guy Bouvier, Yoko Arai, Morgane S. Thion, Ludmilla Lokmane, Maryama Keita, Mario Garcia-Dominguez, Patrick Charnay, Tatsumi Hirata, Dieter Riethmacher, Elizabeth A. Grove, Fadel Tissir, Mariano Casado, Alessandra Pierani, Sonia Garel
Journal: Neuron (2016)
Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers.
Authors: Christina Cognata Smith, D. Alexander Oh, Neha Parikh, Varun Khurana, Santosh Vetticaden
Journal: Journal of Clinical Oncology (2016)

199 Background: Dronabinol, a pharmaceutical tetrahydrocannabinol (THC), capsule is approved for anorexia associated with weight loss in patients with AIDS and for cancer chemotherapy-induced nausea/vomiting in patients with inadequate response to conventional antiemetic therapy. Food effects on absorption and bioavailability of a new dronabinol oral solution was compared with marketed capsules. Methods: In an open-label, single-dose, 3-period crossover study, healthy volunteers were randomized to receive dronabinol oral solution 4.25 mg (fed) or dronabinol capsule 5 mg (fed or fasted), after a 7-day washout period. Doses were administered under a fasted (overnight) or fed state (high-fat/calorie meal 30 minutes pre-dose). Plasma pharmacokinetics was evaluated for dronabinol and the major metabolite, 11-OH-Δ9-THC. Results: Pharmacokinetic data of 54 volunteers were analyzed. In the fed state, initial dronabinol absorption was rapid with oral solution versus capsules (mean T lag , 0.15 vs 2.02 h), and 100% and 15% of volunteers receiving oral solution and capsules, respectively, had detectable plasma dronabinol levels 30 minutes post-dose. Inter-individual variability in plasma dronabinol concentrations during early absorption was less with oral dronabinol solution (%CV: 82.79%, 83.94%, and 90.68%) versus capsules (%CV: 318.54%, 250.33%, and 182.01%) observed at 0.5, 1, and 2 h, respectively, after dosing. Food increased mean AUC 0-t similarly for dronabinol oral solution and capsules, versus capsules with fasting, increasing exposure to oral solution and capsules 2.1- to 2.4-fold. Mean T max was similarly delayed for dronabinol oral solution (7.7 h) and capsules (5.6 h) with food relative to fasting (1.7 h). On the basis of 11-OH-Δ9-THC plasma levels, AUC 0-t up to 48 h postdose and AUC 0-inf were found to be similar for the oral solution and capsules under fed conditions. Conclusions: An appreciable food effect was observed for dronabinol oral solution and capsules. Dronabinol oral solution may offer therapeutic benefit to patients given its rapid absorption and lower inter-individual variability compared with dronabinol capsules. Clinical trial information: NCT01448772.
Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC): Results after 06 years.
Authors: Esma Kerboua, Kamel Bouzid
Journal: Journal of Clinical Oncology (2013)

6075 Background: In squamous cell carcinoma of head and neck cancer, TPF induction CT improved survival over cisplatin plus fluorouracil (Posner MR: NEJM, vol357, Oct 2007). The main objective of this study is to evaluate the activity and safety of TPF in patients (pts) with locally advanced NPC followed by concomitant cisplatin plus radiotherapy (cCTRT). Methods: Pts with undifferentiated NPC were enrolled from December 2006–December 2012 and received 3 cycles of TPF (docetaxel 75 mg/m2 and cisplatin 75/m2 day 1, plus fluorouracil 750 mg/m2 days 1–5, every 4 wks) with G-CSF days 1–5 post CT. CT was followed by cCTRT with cisplatin 40 mg/m2/wk and radiotherapy (65–70 Gy) starting 4–6 wks after the third cycle of CT. The primary endpoint was overall response rate (ORR) after induction CT and after cCTRT. Secondary end points were safety, disease free survival (DFS), and overall survival (OS). Results: 42 pts have been enrolled (26 M/16 F). UICC 1997 classification: n=9 stage II, n=10 stage III, n=23 stage IV. Median age is 37 yrs (range 18–64). Evocative clinical signs are cervical nodes n=20, rhinologic n=13, otologic n=5, and neurologic n=4. All pts were evaluated for safety and 38 for response.TPF well tolerated with main toxicities grade 3–4 (WHO) were neutropenia 36%, thrombocytopenia 32%, anemia 18%, diarrhea 6%, and mucositis 18%. Four pt died from sepsis that was probably treatment-related. ORR was 90% with an 71.4% (n=27) complete response (CR) rate, 23.6% (n=9) partial response (PR), and 5.2% (n=2) stable disease. No pts progressed after induction CT. Main toxicity during cCTRT was neutropenia grade 3–4 in 9%, mucositis grade 3 in 45% and grade 4 in 4%. Late toxicities were xerostomia grade 3 in 50%. At treatment completion, CR and PR rates were 79% and 20%; 2 pts had stable disease. At a median follow up of 72 months (range 7–72), 8% of pts have shown recurrence or progressive disease. DFS and OS rates at 72 months were 65% and 70%, respectively. Conclusions: TPF followed by cCTRT appears to be an active and feasible regimen with a manageable safety profile and may be a promising therapeutic option for pts with high stage NPC.